Importance of inter-hemispheric prefrontal connection in the effects of non-competitive NMDA receptor antagonists
Xavier López-Gil, Laura Jiménez-Sánchez, Tamara Romón, Leticia Campa, Francesc Artigas, Albert Adell
The International Journal of Neuropsychopharmacology July 7, 2011 DOI: 10.1017/s1461145711001064 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical experimental study Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | MK-801 ketamine tetrodotoxin |
| Dose | MK-801 1 mg/kg systemically and 300 μm perfused; ketamine 25 mg/kg systemically and 3 mm perfused; tetrodotoxin 1 μm perfused |
| Measures | in-vivo microdialysis, c-Fos immunohistochemistry, behavioural stereotypy scores |
| Citations | 35 |
| Key findings | Systemic and bilateral, but not unilateral, prefrontal administration of MK-801 and ketamine increased serotonin efflux, whereas only systemic administration produced hyperlocomotion and stereotypies. The authors argue that bilateral impairment of cortical inhibition in the medial prefrontal cortex is needed for non-competitive NMDA antagonists to induce pyramidal cell hyperactivity and concurrent serotonin efflux, and that hyperlocomotion and stereotypies do not appear to result from changes in prefrontal cortex activity. |
Abstract
Previous studies have shown that systemic, but not unilateral intra-prefrontal cortex administration of non-competitive NMDA antagonists, increased prefrontal activity, the cortical efflux of serotonin, and induced stereotypies. In this work we used in-vivo microdialysis and immunohistochemistry to test the hypothesis as to whether MK-801 and ketamine need to act on both prefrontal cortices to reproduce these neurochemical and behavioural changes. Dialysis probes were implanted in the medial prefrontal cortex, and extracellular serotonin as well as behavioural stereotypies was measured after systemic administration of MK-801 and ketamine (1 mg/kg and 25 mg/kg, respectively), and unilateral and bilateral perfusion of both drugs (300 μm and 3 mm, respectively). Additionally, the prefrontal (glutamatergic) level of activity was measured using c-Fos immunohistochemistry. Systemic and bilateral (but not unilateral) prefrontal administration of MK-801 and ketamine increased serotonin efflux whereas only systemic administration of both drugs produced hyperlocomotion and stereotypies. The unilateral perfusion of 1 μm tetrodotoxin in the medial prefrontal cortex reduced increases of serotonin in both hemispheres, the expression of c-Fos in the contralateral side, and stereotypy scores after systemic NMDA antagonists. Our results support the hypothesis that a bilateral impairment of cortical inhibition in the medial prefrontal cortex is needed for non-competitive NMDA antagonists to induce the state of pyramidal cell hyperactivity and concurrent efflux of serotonin. Furthermore, hyperlocomotion and stereotypies produced by MK-801 and ketamine do not appear to result from changes in the activity of prefrontal cortex although this structure exerts some control over these behaviours.
Citations in the library
Cited by 8
- Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies. Pharmacology & Therapeutics July 1, 2019
- Is the Acute NMDA Receptor Hypofunction a Valid Model of Schizophrenia? Schizophrenia Bulletin September 28, 2011
- Is (R)-ketamine a Potential Therapeutic Agent for Treatment-Resistant Depression with Less Detrimental Side Effects? A Review of Molecular Mechanisms Underlying Ketamine and its Enantiomers. Biochemical Pharmacology February 1, 2022
- Effects of Hallucinogens on Neuronal Activity. Current Topics in Behavioral Neurosciences 2018
- Ketamine and sleep modulate neural complexity dynamics in cats. European Journal of Neuroscience March 1, 2022
and 3 more in the library
Cites 6
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Recent advances in the phencyclidine model of schizophrenia American Journal of Psychiatry October 1, 1991
- Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex Journal of Neuroscience April 15, 1997
- Activation of thalamocortical networks by the N-methyl-D-aspartate receptor antagonist phencyclidine: reversal by clozapine. Biological Psychiatry May 15, 2011
- Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends in Neurosciences June 1, 2001
and 1 more in the library